ReproCELL Incorporated (TYO:4978)
151.00
+6.00 (4.14%)
Apr 25, 2025, 3:30 PM JST
ReproCELL Revenue
ReproCELL had revenue of 748.00M JPY in the quarter ending December 31, 2024, with 18.92% growth. This brings the company's revenue in the last twelve months to 2.72B, up 8.46% year-over-year. In the fiscal year ending March 31, 2024, ReproCELL had annual revenue of 2.43B, down -17.85%.
Revenue (ttm)
2.72B
Revenue Growth
+8.46%
P/S Ratio
5.26
Revenue / Employee
28.31M
Employees
96
Market Cap
14.30B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 2.43B | -527.00M | -17.85% |
Mar 31, 2023 | 2.95B | 719.00M | 32.18% |
Mar 31, 2022 | 2.23B | 948.00M | 73.72% |
Mar 31, 2021 | 1.29B | 87.00M | 7.26% |
Mar 31, 2020 | 1.20B | 111.00M | 10.20% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,170.61B |
Takeda Pharmaceutical Company | 4,579.02B |
Daiichi Sankyo Company | 1,795.99B |
HOYA Corporation | 838.60B |
Terumo | 1,011.15B |
Otsuka Holdings | 2,329.86B |
Astellas Pharma | 1,867.63B |
Shionogi & | 456.87B |